Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
NCT ID: NCT07339488
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
43 participants
INTERVENTIONAL
2025-11-01
2028-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Current conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.
Retrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.
Based on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR/UR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR/UR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg/m² on day 1), cisplatin (75 mg/m² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
NCT04973306
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
NCT05394415
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
NCT05628610
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ILDR plus immunochemotherapy plus surgery
1Gy/1F ILDR + albumin-bound paclitaxel (3 cycles of 260 mg/m² on day 1), cisplatin (3 cycles of 75 mg/m² on day 1), and tislelizumab (3 cycles of 200 mg on day 1) + surgery
Intestinal Low Dose Radiotherapy-1Gy
1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
PD-1/PD-L1 inhibitors
3 cycles of tislelizumab（200 mg D1 q3w）
Chemotherapy
3 cycles of albumin-bound paclitaxel（260 mg/m2 D1 q3w）+ cisplatin（75 mg/m2 D1 q3w）
Surgery
McKeown esophagectomy or laparoscopic-assisted McKeown esophagectomy is recommended, with either two-and-a-half-field lymphadenectomy or three-field lymph node dissection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intestinal Low Dose Radiotherapy-1Gy
1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
PD-1/PD-L1 inhibitors
3 cycles of tislelizumab（200 mg D1 q3w）
Chemotherapy
3 cycles of albumin-bound paclitaxel（260 mg/m2 D1 q3w）+ cisplatin（75 mg/m2 D1 q3w）
Surgery
McKeown esophagectomy or laparoscopic-assisted McKeown esophagectomy is recommended, with either two-and-a-half-field lymphadenectomy or three-field lymph node dissection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 years and ≤75 years; both sexes are eligible.
3. ECOG performance status score of 0-1.
4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.
5. Thoracic esophageal cancer.
6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.
7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
8. Baseline laboratory requirements (within 7 days prior to enrollment):
Hematology:
1. Hb≥90 g/L (no transfusion within 14 days)
2. NEUT ≥1.5×10⁹/L
3. PLT ≥100×10⁹/L
4. WBC≥3×10⁹/L
Biochemistry:
1. ALT and AST≤2.5×ULN
2. TBIL≤1.5×ULN
3. SCr≤1.5×ULN; or CrCl≥60 mL/min Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: LVEF≥50%
9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.
10. No psychological, familial, social, or geographical factors that may impair protocol adherence.
11. Other parameters meet general clinical trial enrollment criteria.
12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.
Exclusion Criteria
2. Presence or high risk of esophageal perforation.
3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.
4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.
5. Patients with a history of thoracoabdominal/pelvic radiotherapy within 6 months prior to enrollment.
6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).
7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.
8. Respiratory depression, airway obstruction, or tissue hypoxia.
9. Severe cardiac disease (i.e., NYHA functional class II or higher).
10. Markedly abnormal liver or kidney function (i.e., indicators \>3 times the upper limit of normal).
11. Active hepatitis B, hepatitis C, HIV, or syphilis.
12. Active brain disease or central nervous system/meningeal metastases with significant symptoms, or impaired decision-making capacity.
13. Hypersensitivity to drugs included in the trial.
14. Drug and/or alcohol abuse.
15. Pregnant or lactating women.
16. Concurrent participation in another therapeutic clinical trial.
17. Major surgical procedure within 30 days prior to enrollment.
18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BeOne Medicines
INDUSTRY
Chuangzhen Chen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chuangzhen Chen
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUMC-ILDR03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.